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ORIGINAL ARTICLE
Positive effects of methylphenidate on hyperactivity are moderated
by monoaminergic gene variants in children with autism spectrum
disorders
JT McCracken1, KK Badashova1, DJ Posey2, MG Aman3, L Scahill4, E Tierney5, LE Arnold3, B Vitiello6, F Whelan1, SZ Chuang7, M Davies7,
B Shah1, CJ McDougle8 and EL Nurmi1
Methylphenidate (MPH) reduces hyperactive-impulsive symptoms common in children with autism spectrum disorders (ASDs),
however, response and tolerability varies widely. We hypothesized monoaminergic gene variants may moderate MPH effects in
ASD, as in typically developing children with attention-deficit/hyperactivity disorder. Genotype data were available for 64 children
with ASD and hyperactivity who were exposed to MPH during a 1-week safety/tolerability lead-in phase and 58 who went on to be
randomized to placebo and three doses of MPH during a 4-week blinded, crossover study. Outcome measures included the Clinical
Global Impression-Improvement (CGI-I) scale and the Aberrant Behavior Checklist (ABC-hyperactivity index). A total of 14 subjects
discontinued the study because of MPH side effects. Subjects were genotyped for variants in DRD1–DRD5, ADRA2A, SLC6A3, SLC6A4,
MAOA and MAOB, and COMT. Forty-nine percent of the sample met positive responder criteria. In this modest but relatively
homogeneous sample, significant differences by DRD1 (P¼ 0.006), ADRA2A (Po0.02), COMT (Po0.04), DRD3 (Po0.05), DRD4
(Po0.05), SLC6A3 (Po0.05) and SLC6A4 (Po0.05) genotypes were found for responders versus non-responders. Variants in DRD2
(Po0.001) and DRD3 (Po0.04) were associated with tolerability in the 14 subjects who discontinued the trial. For this first MPH
pharmacogenetic study in children with ASD, multiple monoaminergic gene variants may help explain individual differences in
MPH’s efficacy and tolerability.
The Pharmacogenomics Journal (2014) 14, 295–302; doi:10.1038/tpj.2013.23; published online 16 July 2013
Keywords: autism spectrum disorders; dopamine; genetics; hyperactivity; methylphenidate
INTRODUCTION
The autism spectrum disorders (ASDs) are a group of neurodeve-
lopmental disorders including autistic disorder, Asperger’s disorder
and pervasive developmental disorder, not otherwise specified,
which share impairment in social communication. Surveys estimate
1 out of 88 to 160 children as having an ASD.1 Impairment from
ASD varies considerably across its core dimensions, but also from
associated maladaptive behaviors, such as symptoms resembling
attention-deficit/hyperactivity disorder (ADHD).2–4 Moderate-to-
severe hyperactive-impulsive behaviors overlap in one-third or
more individuals with ASD. These behaviors are often targeted by
pharmacologic and other treatment efforts,5,6 such as stimulants.
Despite common use of stimulants for ASD,7,8 variable effects
and reduced tolerability was suggested from small early studies,9–12
but no moderators of response have been reported. In the
largest stimulant trial in ASD, the Research Units on Pediatric
Psychopharmacology (RUPP) Autism Network (2005) found
methylphenidate (MPH) was superior to placebo in reducing
ratings of hyperactivity,13,14 but only half (35/72; 49%) were
considered clinical responders. In addition, 19% of subjects were
withdrawn because of adverse effects; variability in optimal dose,
adverse events and response was striking.15
Variability in response to stimulant treatment is well known in
typically developing children,16 and there is interest in individual
genetic variation moderating response in the treatment of
ADHD.17,18 However, no reports examining the pharmacogenetics
of stimulant response exist for children with ASD. In addition,
although a small number of reports have described genetic
associations with adverse events and stimulants, none in typical
ADHD or subjects with ASD have examined possible genetic
associations in those with ‘intolerable’ side effects leading to dropout.
Investigations in typically developing children have suggested
that variants in catecholamine-related genes may be associated
with MPH response in ADHD.17 The majority of these examined
the variable number tandem repeat (VNTR) polymorphism
located in the 30 untranslated region of the dopamine
transporter gene (SLC6A3),17,19,20 the site of MPH action. A meta-
analysis has suggested that the nine-repeat variant may confer
reduced efficacy;21 however, recent reports showed enhanced
response of 9/9 homozygotes with a dose-dependent effect.22
Investigations of stimulant response and the 48-base pair (bp)
VNTR polymorphism in exon 3 of the dopamine D4 receptor
(DRD4) gene17 have been mixed, with greater efficacy seen in
subjects with one or two copies of the four-repeat VNTR genotype
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(DRD4.4),23–25 while others found opposite26 or no effects.27–29
Variants such as DAT1 9/10, DRD4.7 and the a-adrenergic receptor
2A (ADRA2A) influence the slope of dose-response relations.19,22
Few data are available regarding the impact of variation in other
dopamine (DA)- receptors DRD1, DRD2, DRD3 or DRD5. Although
data are sparse and conflicting, some reports have associated
MPH side effects with variants in DAT1 and DRD4 as well.19,25,30
Awareness of pharmacogenetic interactions of other neuro-
transmitter genes with psychostimulant action has grown.
Variants in ADRA2A influence response of inattentive symptoms
to MPH.22,31,32 Interactions between DA and serotonin (5HT) have
also been suggested as integral to MPH’s behavioral and
locomotor effects.33 Two studies presented significant
moderating effects of the 44-bp insertion–deletion polymorphism
in the promoter region of the serotonin transporter gene
(SLC6A4),19,34 although one report did not detect an effect.29
Genetic variants in COMT also influence basal transmitter
availability,35 working memory36 and cognitive response to
acute stimulant administration.37 In ADHD, three reports concur
that the Val158Met COMT variant moderates MPH effects.19,38,39
Variability in existing ADHD pharmacogenetic studies reflect the
heterogeneity in methodology and outcomes. MPH dosing differs,
there are few randomized, blinded, placebo-controlled studies,
and only four assessed outcomes at multiple doses.19,20,25,31
The purpose of this preliminary investigation was to thoroughly
evaluate for the first time in subjects with ASD whether gene
variants in candidate loci would be found to associate with the
overall clinical response to MPH. Candidates were suggested as
moderators by at least two prior pharmacogenetic studies of MPH
(DRD4, SLC6A3, SLC6A4, COMT and ADRA2A), risk genes for ADHD,
known targets of MPH action (DRD1, DRD2 and DRD5)40 or
associated with psychomotor functioning and impulsivity (DRD2
and DRD3).41,42 We hypothesized that gene variants suggested to
exert significant effects on MPH response in typically developing
children would also influence effects on response and tolerability
in a homogeneous sample of children with ASD. However, we
noted the multiple findings suggesting dysregulated DA function
in ASD,43–45 which could alter the relations between gene variants
and MPH response and tolerability.
MATERIALS AND METHODS
Subjects
The details of the recruitment and baseline characteristics of the sample
have been described previously.46 Briefly, subjects were recruited at the
five centers that formed the RUPP Autism Network funded by the National
Institute of Mental Health (NIMH). The study was approved by each local
institutional review board and monitored by a central NIMH data and
safety monitoring board. Written informed consent was obtained from a
parent or guardian, and assent was given by the child when capable.
To be eligible for the study, subjects from 5 to 14 years were required to
meet Diagnostic and Statistical Manual, version-IV criteria for autistic
disorder, Asperger’s disorder, or PDD-NOS using clinical examination and
the Autism Diagnostic Interview-Revised,47 with diagnoses following
Diagnostic and Statistical Manual, version-IV criteria. All subjects had
significant symptoms of ADHD (based on the Clinical Global Impression
(CGI)-Severity and Swanson, Nolan, and Pelham-IV (SNAP-IV)), were
medically healthy, and were not taking any concomitant psychotropic
drugs during the treatment phase of the study.
Study design
Details of the study’s design and rationale were published previously.46
Briefly, it included a 1-week test dose phase of 1-day placebo, and 2 days
each of the low, medium and high MPH doses used in the next phase to
determine initial MPH tolerability, followed by a 4-week random-order,
placebo-controlled, double-blind crossover phase to assess efficacy, and an
8-week open-label continuation phase for subjects showing a positive
response to assess the maintenance of beneficial effects.
Subjects who were unable to tolerate MPH during the test dose phase as
evidenced by a CGI rating of ‘much worse’ or ‘very much worse’ at a low or
medium dose of MPH were excluded before being randomized. Subjects
who tolerated all three dose levels of MPH during the test dose phase
entered into the 4-week double-blind crossover phase. Each subject
received placebo and three different doses of MPH in random order,
1-week each.
Low, medium and high doses of MPH were assigned based on body
weight to approximate 0.125, 0.25 and 0.5mgkg–1 per dose, administered
morning and noon, with an additional half-dose given at 1600 hours.
Subjects with moderate or greater side effects to the highest dose level of
MPH in the test dose phase received the medium dose during 2 weeks of
the double-blind, crossover phase. Clinicians, the patient and the caregiver
were blind to treatment assignment during the crossover phase.
Positive response was defined as a rating of ‘much improved’ or ‘very
much improved’ on the CGI completed by the masked study clinician and
a significant reduction on the Aberrant Behavior Checklist (ABC)-
hyperactivity subscale (defined as a 25% reduction by both parent and
teacher or a 30% reduction by parent or teacher) at any given weekly
assessment during the blinded phase, and completion of all weeks of the
blinded phase. For the purpose of these responder analyses, subjects who
dropped out at any point after entering the double-blind phase (n¼ 8) are
grouped with non-responders. For the purpose of tolerability analyses, any
subject who dropped out in either the test dose or double-blind phase
secondary to adverse events formed the intolerant group (n¼ 14).
Genotyping
Ten candidate genes were selected for typing. A total of 36 variants were
genotyped across the 10 loci. Common (410%) locus variability was
captured across the dopamine receptor genes DRD1–DRD5, ADRA2A,
MAOA and MAOB, and SLC6A4. Several known functional variants were also
genotyped, including the Val158Met COMT non-synonymous single-
nucleotide polymorphism (SNP),19 and VNTRs in SLC6A3 (480-bp VNTR in
the 30 untranslated region),17 DRD4 (exon 3 48-bp VNTR)48 and SLC6A4 (44-
bp insertion–deletion in the promoter region (5-HTTLPR) with modifying
SNP (rs25531) and intron 2 VNTR (STin2)).49 To minimize multiple testing of
non-independent genotypes, allele frequencies were computed and geno-
type classifications defined a priori to any outcome analyses.
The SLC6A3 VNTR (DAT1) was genotyped using published methods and
primers.50 The DRD4-exon 3 VNTR was genotyped with the following
modified primers: F—5’-CTACCCTGCCCGCTCATG-3’; R—5’-CCGGTGATCTTG
GCACGC-3’ using previously described methods.51 The SLC6A4 promoter
region gene-linked polymorphic region (5-HTTPLR) short–long variant and
intron 2 10/12 VNTR (STin2) were genotyped according to published
protocols.52 For VNTR variants (5-HTTLPR, 5-HTT STin2, DAT and DRD4), PCR
products were electrophoresed in 2% gold agarose (BMA, Rockland, ME, USA)
gels in 1x TBE and imaged with ethidium bromide under fluorescent Kodak
digital camera (Rochester, NY, USA). Alleles were determined by comparison
with molecular weight standards and control individuals with previously
determined genotypes. Samples were double-scored by two technicians.
Tag SNPs were selected using Haploview Software53 publicly available
from the HapMap Consortium to capture variability present atX10% with
an r2X0.8. SNPs were genotyped using the Life Technologies (Life
Technologies, Grand Island, NY, USA) TaqMan platform with Qiagen Type-it
Fast SNP Probe PCR Kit (Qiagen, Valencia, CA, USA) according to the
manufacturer’s protocols. All genotypes were in Hardy–Weinberg Equili-
brium (P40.05). Ten percent of the data set was genotyped in duplicate
without any conflicting genotypes, and allele frequencies were checked for
consistency with those reported by the HapMap Consortium.
Potential functional roles of associated non-coding variants were
explored using the online UCSC Genome Browser54 with ENCODE
tracks55 and the Broad Institute’s Haploreg online resource.56
Data analysis
All subjects randomized to the double-blind crossover phase were
included in the responder analyses. Descriptive statistics are reported as
the mean±s.d. Before examining allelic effects on response, a general
linear model was constructed using the ABC-hyperactivity for each gene
variant examined to test for the presence of a positive dose effect (for
example, if a treatment effect existed). Dose (low, medium, high or
placebo), genotype and the interaction dose by genotype were then
entered as predictor variables of parent-rated ABC-hyperactivity scores.
The primary analyses were response by genotype compared using w2
analyses or Fisher’s exact tests. As the DRD3 gly allele is the minor variant
and some prior reports have shown biological differences between ser/ser
and ser/gly versus gly/gly genotype groups, we restricted our comparison
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accordingly.57 As some investigators have noted significant moderation of
stimulant effects of DRD4 variants in typically developing children
specifying genotypes by the presence of 0, 1 or 2 copies of the ‘7’
allele,19 we also performed a similar three-way grouped analysis for this
variant. Based on the fact that the previous literature on the SLC6A3 VNTR
has shown significant effects for 9/9 homozygotes, we analyzed our data
according to this model.22 Statistical significance was set as Po0.05, and
Po0.002 with correction for multiple testing.
RESULTS
Sixty-six children with autistic disorder (n¼ 47), Asperger’s
disorder (n¼ 5) or pervasive developmental disorder, not other-
wise specified (n¼ 14) completed the test dose phase and entered
the double-blind crossover phase. Six subjects discontinued
during the test dose phase. Of the 72 subjects who entered the
trial, 7 subjects were unable or refused to provide samples for
DNA and data were missing for one subject, leaving 64 subjects
for genotyping. Sixteen subjects received an additional week of
medium dose during the crossover phase because of moderate or
greater side effects to the high dose in the test dose phase. Fifty-
eight subjects were able to complete all 4 weeks of the crossover
with the remainder leaving either because of adverse events
(n¼ 7) or for other reasons (n¼ 1). The mean age of the subjects
in this report was 6.90 years (±2.2, range 5.0–13.0); 75.9% were
Caucasian, 87.9% were male; the mean intelligence quotient was
65.0 (±33.3 range¼ 16–135). Neither age, ethnicity nor diagnosis
was a significant covariate.
Table 1 shows parent and teacher rated SNAP-ADHD, SNAP-
ODD and ABC-hyperactivity at baseline before entry into the
double-blind phase. In general, subjects in the study had
moderately severe symptoms of ADHD, and the optimal dose
week demonstrated a moderate benefit associated with signifi-
cantly reduced ABC-hyperactivity ratings and lower CGI-I scores.
Analyses of ABC-hyperactivity scores across all four dose assess-
ments showed a main effect for dose for all genotypes (all
Po0.001). Variability in individual dose-response trajectories and
optimal dose was substantial (Figure 1).
After grouping subjects by a priori defined responder or non-
responder categories, we analyzed the association of genotypes
with responder status. Table 2 reports the results of w2 tests for
genotype by response. Nominally significant responder by
genotype effects (Figure 2) were noted for the dopamine receptors
DRD1 rs5326 (P¼ 0.006, Figure 2a) and rs4867798 (Po0.05,
Figure 2b), DRD3 ser9gly rs6280 (Po0.05, Figure 2c) and DRD4
rs11246226 (Po0.04, Figure 2d); the adrenergic receptor ADRA2A
rs1800544 (Po0.02, Figure 2e); the dopamine and serotonin
transporters SLC6A3 VNTR (Po0.05, Figure 2f) and SLC6A4 STin2 VNTR
(Po0.05, Figure 2g), respectively; and the catabolic enzyme COMT val/
met rs4680 (Po0.05, Figure 2h). No significant effects on response
were evident for the DRD2, DRD5 or MAOA/B variants tested.
In an effort to further reveal possible interactions between dose
condition and genotype, in secondary analyses we tested the
relationship between ABC-hyperactivity scores across the four
treatment conditions for main effects of dose, genotype and dose
by genotype interaction using analysis of covariance with baseline
ABC-hyperactivity scores as the covariate. Results (Table 2) showed
significant dose by genotype interactions for promoter SNPs in
DRD4 rs11246226 (Po0.02) and SLC6A4 rs12150214 (Po0.03). In
contrast to previous findings, SLC6A3 VNTR analysis did not yield
dose by genotype effects;22 however, our power to detect these
effects was very low given the small number of subjects with the
9/9 genotype (n¼ 3), all of whom were responders.
The 14 subjects who dropped because of intolerability were
similar to those completing the study (83% male, 83% Caucasian,
mean age 8.6 years). Genetic comparison of those 14 subjects to
trial completers revealed a protective effect for carriers of the
minor allele at DRD2 synonymous variant rs6275. Intolerability
increased from 4% in minor allele carriers to 23% in those
homozygous for the common allele (Po0.001), a result surviving
correction for multiple testing. The DRD3 variant rs6280 (Ser9Gly)
was nominally associated with tolerability, as intolerability
increased from 3% in common allele homozygotes to 18% in
carriers of the minor allele (P¼ 0.031), suggesting that the minor
allele is a risk factor for stimulant intolerance.
DISCUSSION
In this first pharmacogenetic study of MPH in a modest but
homogeneous (90% male, 90% stimulant naive) sample of
children with ASD, improvement in hyperactive-impulsive symp-
toms associated with MPH administration was moderated
significantly by several gene variants comprising elements of
monoaminergic systems for dopamine, norepinephrine and
serotonin, all of which have known regulatory effects on motor
activity, and higher order cognitive functions.58–60 Of the 10
candidate genes queried based on prior research, our data
supported a contribution of genetic variation in 7 genes (SLC6A4,
Table 1. ABC-hyperactivity ratings and SNAP ratings in genotyped
children with ASD (n¼ 58) at entry into the double-blind phase
Outcome measure N Mean
(±s.d.)
Item mean
(±s.d.)
Parent SNAP-IV ADHD (18 items) 58 39.1±7.9 2.26±0.43
Parent SNAP-IV ODD (8 items) 58 9.67±6.17 1.21±0.78
Parent ABC-hyperactivity rating at
baseline (16 items)
58 33.6±7.43 2.09±0.47
Teacher SNAP-IV ADHD (18 items) 54 35.74±8.23 2.05±0.46
Teacher SNAP-IV ODD (8 items) 54 8.48±4.64 1.07±0.59
Teacher ABC-hyperactivity rating
(16 items)
54 31.46±8.68 1.94±0.55
Abbreviations: ABC, Aberrant Behavior Checklist; ADHD, attention-deficit/
hyperactivity disorder; ASD, autism spectrum disorder; ODD, oppositional
defiant disorder; SNAP-IV, Swanson, Nolan, and Pelham-IV.
Varying sample size (N) because of missing teacher data on six subjects.
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Figure 1. Individual parent-rated Aberrant Behavior Checklist (ABC)-
hyperactivity scores during double-blind crossover trial. Top panel
includes non-responders; bottom panel responders (see text for
definition). Individual weekly ratings obtained at baseline and during
random-order crossover weeks of methylphenidate treatment.
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SLC6A3, DRD1, DRD3, DRD4, COMT and ADRA2A) to clinical MPH
response. Although our sample size did not provide adequate
power for multiple comparison correction, the number of positive
associations observed is unlikely to occur by chance. An exact
binomial calculation for the probability of 7 or more significant
hits out of 36 variants, whereas not an exact P-value, suggests that
many of these associations are in fact true positives (Po0.002).
These genetic effects may reveal some of the sources of marked
variability in clinical outcomes observed in this trial and in clinical
experience for this common treatment in ASD; in this trial only half
of all subjects responded to moderate-dose MPH.
Our results add support to the previous suggestions of
contributions of variants in several genes influencing MPH
response in ADHD (SLC6A4, SLC6A3, DRD4, COMT and ADRA2A)
but in some cases suggest new loci not previously implicated as
MPH-response modifiers (SLC6A4 STin2 VNTR and DRD4
rs11246226). In addition, we also identified new associations with
other genes not extensively examined thus far in the ADHD
literature (DRD1 rs5326 and rs4867798, DRD3 ser9gly rs6280),
but rational candidates given their distribution and known
cognitive and behavioral pharmacologic effects of agonists and
antagonists at these targets. Our findings should encourage other
investigations of these variants in larger samples.
Not surprisingly, DA transporter and DA receptor variants
showed the strongest associations with treatment response. In
contrast to earlier studies,19,20,61 our data agree with the recent
report by Froehlich et al.,22 showing an enhanced MPH response
in SLC6A3 9/9 homozygotes. DRD1, highly expressed in cortex and
striatum, is important in cognitive and motor control,62 and may
be a minor ADHD risk gene.63,64 DRD1 was most strongly
associated with clinical response with two SNPs (rs5326 and
rs4867798; P¼ 0.006 and P¼ 0.043, respectively) in our sample. In
silico exploration suggests that both DRD1 SNPs (rs5326 and
rs4867798) may be functional, as they map to areas of open
chromatin in the 50 and 30 untranslated regions and appear to
alter binding sites for the transcriptional repressor ZNF263 and
the transcriptional activator POU2F1 respectively. The non-
synonymous Ser9Gly variant in DRD3 was also associated with
Table 2. MPH responder/non-responder number by genotypes from double-blind crossover trial
Gene Variant Alleles Responder
% (n)
Non-responder
% (n)
Genotype responder
status P-value
Dose genotype
P-value
DRD1 rs4867798 Cþ 67% (22/33) 33% (11/33) 0.042 0.577
TT 40% (10/25) 60% (15/25)
rs5326 Tþ 82% (14/17) 18% (3/17) 0.006 0.215
CC 44% (18/41) 56% (23/41)
rs686 0.796
DRD2 rs6277
rs6589377 0.714
rs4938019 0.292
rs7131056 0.505
rs1800498 0.714
rs2283265 0.566
rs6275 0.148
rs1800497 0.660
DRD3 rs6280 Ser/Ser 74% (14/19) 26% (5/19) 0.044 0.569
(Ser9Gly) Glyþ 46% (18/39) 54% (21/39)
rs2134655 0.696
rs9880168 0.259
rs7633291 0.404
rs167771 0.795
rs3732790 0.397
DRD4 rs11246226 AA 79% (11/14) 21% (3/14) 0.038 0.013
Cþ 48% (21/44) 52% (23/44)
rs3758653 0.271
Exon 3 VNTR 0.810
DRD5 rs10033951 0.930
SLC6A3 3’UTR VNTR 10þ 51% (27/53) 49% (26/53) 0.049 0.316
9/9 100% (3/3) 0% (0/3)
SLC6A4 rs12150214 0.078 0.026
rs4251417 0.577
rs11080121 0.642
5HTT-LPR 0.881
STin2 VNTR 10þ 67% (22/33) 33% (11/33) 0.041 0.764
12/12 39% (9/23) 61% (14/23)
ADRA2A rs1800544 CC 71% (20/28) 29% (8/28) 0.015 0.790
Gþ 40% (12/30) 60% (18/30)
rs12246561 0.319
rs3750625 0.546
MAOA/B rs1465108 0.501
rs3810709 0.416
rs3027399 0.073
rs10521432 0.308
rs1799836 0.191
COMT rs4680 Metþ 64% (25/38) 36% (13/38) 0.049 0.576
(Val158Met) Val/Val 36% (7/19) 63% (12/19)
Abbreviation: MPH, methylphenidate.
Shaded values indicate significant P-values.
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MPH response. Ser/ser homozygotes demonstrated greater
response than glycine allele carriers. Finally, we observed an
association of a promoter SNP (rs11246226) in DRD4 with both
clinical response as well as a genotype by dose interaction. DRD4
is well known as a minor risk gene for ADHD65 and the exon 3
VNTR has been extensively studied for associations with cognitive
phenotypes and drug response, but studies have not tested
effects of other variants at this locus. It is difficult to ascertain the
likely sources of differences between our data and some previous
studies for effects of the DRD4 exon 3 VNTR variant in particular,
however, we note the literature is quite inconsistent with respect
to its associations with response, even in reports from the same
group.19,25 Consistent with other reports, DRD2 was not found to
associate with clinical response to MPH, surprising given the
multiple functional variants and stimulant-induced displacement
of DRD2 binding following acute MPH.40 Taken together, our
findings of associations between DRD1, DRD3 and DRD4 and
response measures suggest that common variants in the DA
pathway do exert influences on the effects of MPH and moderate
its DA-mediated impact on behavior.
Despite our modest sample size, the multiple (admittedly
nominal) associations with several dopamine receptor subtypes
(DRD1, DRD3 and DRD4) lead us to speculate that the effects of
gene variants in these targets may be amplified by ASD-related
dopamine dysregulation. We posit that ASD-related differences in
DA function may influence the interaction between gene variants
and MPH, as evidence supports increased DA turnover (increased
frontal uptake of18 fluoro-3,4-dihydroxy-5-fluorophenylalanine and
increased cerebrospinal fluid homovanillic acid) in ASD as well as
increased dopamine transporter binding.44,45,66 Such ASD-related
differences may shift dose-response, enhancing or distorting
pharmacogenetic relationships seen in typically developing
children. Indeed, the high rate of MPH intolerance, several-fold
greater than reports from typically developing children, suggests
greater sensitivity to MPH pro-dopaminergic effects in ASD. These
data add modest support to the notion that although common
gene variants influence psychostimulant response in both
typically and atypically developing subjects with hyperactivity,
there are some possible differences because of underlying
disorder neurobiology.
Our findings also reinforce the emerging view that beneficial
effects of stimulants are multifactorial in their mechanism,
reflecting drug effects on serotonergic and noradrenergic func-
tions in addition to dopaminergic actions.59 However, it is possible
that identified non-DA gene effects may be also mediated via
downstream effects on dopaminergic neurotransmission. For
example, SLC6A4 alleles associated with high expression (LPR l
and particularly STin2 12 alleles), have been suggested to
moderate mood effects of amphetamine in healthy subjects52
and in typically developing children with ADHD, and LPR l/l
homozygous subjects showed less improvement in global
functioning with MPH.34 However, opposing effects of the two
variants were seen on different outcome variables.19 Mice lacking
SLC6A3 still demonstrate reductions in activity from MPH,
apparently mediated via 5HT.33 The lower response rates in our
10/12 and 12/12 genotype subjects is in line with the known
effects of the 12 allele on higher transporter expression. We also
noted a tagging SNP in the first intron of SLA6A4, just upstream of
the translational start, was associated with differential response at
high dose MPH. This SNP, while intronic, is in a linkage
disequilibrium block showing multiple enhancer histone marks
suggesting an area of active transcriptional regulation.
Similarly, these data also contribute to the growing support for
the involvement of the noradrenergic system in stimulant
response in ADHD, consistent with direct effects of stimulant-
induced NE release58 and the reciprocal relationship of
noradrenergic–dopaminergic pathways.67 Our data did identify a
moderating effect of the ADRA2A promoter SNP rs1800544 and
clinical response, extending prior observations.31,32 Online
database mining supports a functional effect of the associated
variant, as this SNP maps to a site of open chromatin in the
ADRA2A promoter with histone marks and binding sites for the
transcription factors RAD21 and CTCF, which have a role in
promoter methylation, and ultimately expression.
Relevant to dopaminergic and noradrenergic transmission, we
found support for earlier observations19,38,39 that variants in COMT
moderated clinical benefit from MPH. However, contrary to studies
in healthy subjects37 and typical ADHD, in our data set met-carriers
showed a greater reduction in hyperactivity with MPH treatment
than val/val homozygotes. Indeed, met/met subjects had a 75%
(9/12) response rate versus 37% (7/19) for val/val homozygotes,
a twofold differential. If ASD is associated with reduced tonic
dopamine (consequences of increased DAT and increased pre-
synaptic uptake), the resulting hypothesized shift in dose-response
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Figure 2. Genotype associations with methylphenidate clinical response rates. Positive response defined as Clinical Global Impression-
Improvement (CGI-I) rating by blinded study clinician of ‘much improved’ or ‘very much improved’ and decrease in parent-rated Aberrant
Behavior Checklist-Hyperactivity subscale of425% from baseline for any active drug week. n¼ 58 subjects. P-values reflect results of w2 tests.
Panels a–h are plots of genotype group and their respective response rates for: 2a) DRD1 rs5326; 2b) DRD1 rs4867798; 2c) DRD3 rs6280; 2d)
DRD4 rs11246226; 2e) ADRA2A rs1800544; 2f ) SLC6A3 VNTR; 2g) SLC6A4 STin2; 2h) COMT rs4680.
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could favor met/met individuals, as val/val subjects may lack
sufficient dopamine availability to overcome reduced DA tone
despite MPH releasing effects.
Our report is novel in our analyses of possible genetic
underpinnings of stimulant intolerance, not heretofore researched
in the ADHD pharmacogenetic literature. A DRD2 variant, rs6275,
not associated with response, was significantly associated with
MPH intolerability and remained significant after correction.
Homozygotes for the common allele at rs6275 showed a sixfold
greater rate of intolerance. The non-synonymous Ser9Gly (rs6280)
variant in DRD3 was associated with MPH response and
tolerability, as gly allele carriers were highly likely to either be
intolerant of MPH and/or be less responsive than ser/ser
homozygotes. These variants merit additional investigation in
relationship to a range of stimulant-induced adverse effects in
much larger samples.
Strengths of our findings include the thorough genetic analyses,
use of a rigorous study design including comparisons of placebo
versus multiple fixed-dose treatment conditions, blinded evalua-
tions by multiple informants (parents, teachers and study
clinicians), application of a careful, multi-informant based and
clinically relevant definition of responder status, and recruitment
of a largely male, stimulant-naive, homogenous sample. Relative
to the only other small (np13), controlled studies of stimulants in
ASD, our sample is more homogenous with respect to sex,
ethnicity, treatment history and diagnosis.11,12 Capitalizing on the
strengths of our design, we were able to examine genetic effects
observed under optimal treatment conditions, as determined by
blinded assessments and multiple raters.
Limitations of this work include the short duration of MPH
treatment observation periods, the modest sample size and the
restrictions of genotyping to selected candidate genes. Our
observations could be associated with an increased risk of type I
statistical error.
In summary, the reduction of hyperactivity by MPH in
individuals with ASD may be moderated at the level of individual
genetic variability, particularly at loci that influence monoaminer-
gic signaling. ADHD symptoms are common in ASD, and MPH
remains the best empirically validated treatment for this target,
although variation in response and tolerability is large. Additional
studies replicating our observations and identifying other
potential individual predictors of response to MPH in individuals
with ASD are strongly needed. Improving overall outcomes from
long-term intervention efforts for ASD remains a major clinical and
public health challenge.
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